drugset / Trial / NCT00407381
The Ranibizumab for Edema of the mAcula in Diabetes-2 (READ-2) Study
Phase 2
Completed
126 enrolled
Johns Hopkins University
Genentech, Inc. · collabJuvenile Diabetes Research Foundation · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
This study is being done to see if the investigational drug Ranibizumab (RBZ) given by injection into the eye, is safe and effective to use in people with diabetic macular edema (DME). The investigators want to compare RBZ to laser treatment which is the current standard way to treat DME. RBZ blocks a growth factor that is thought to be involved in the formation of abnormal blood vessels that cause loss of vision in patients with DME.
Timeline
- Start
- 2006-12
- Primary completion
- 2010-08
- Completion
- 2011-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ranibizumab | Monoclonal antibody | 0.05 ml | Intravitreal |
| Subject | Ranibizumab | Monoclonal antibody | 0.5 mg | Intravitreal |